[1]李芳芳,于 佳.重组人干扰素α-2b雾化治疗儿童呼吸道病毒感染性疾病的临床效果[J].医学信息,2021,34(23):120-122.[doi:10.3969/j.issn.1006-1959.2021.23.035]
　LI Fang-fang,YU Jia.Clinical Effect of Recombinant Human Interferon α-2b Atomization in the Treatment of Children with Respiratory Viral Infectious Diseases[J].Medical Information,2021,34(23):120-122.[doi:10.3969/j.issn.1006-1959.2021.23.035]
点击复制

重组人干扰素α-2b雾化治疗儿童呼吸道病毒感染性疾病的临床效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年23期
页码:
120-122
栏目:
论著
出版日期:
2021-12-01

文章信息/Info

Title:
Clinical Effect of Recombinant Human Interferon α-2b Atomization in the Treatment of Children with Respiratory Viral Infectious Diseases
文章编号:
1006-1959（2021）23-0120-03
作者:
李芳芳; 于 佳
（天津市滨海新区海滨人民医院儿科1，消化内科2，天津 300280）
Author(s):
LI Fang-fang; YU Jia
(Department of Pediatrics1,Department of Gastroenterology2,Haibin People’s Hospital of Tianjin Binhai New Area,Tianjin 300280,China)
关键词:
病毒感染; 呼吸道疾病; 重组人干扰素α-2b; 免疫球蛋白
Keywords:
Virus infection; Respiratory diseases; Recombinant human interferon α-2b; Immunoglobulin
分类号:
R511.7
DOI:
10.3969/j.issn.1006-1959.2021.23.035
文献标志码:
A
摘要:
目的 探究重组人干扰素α-2b（rhIFNα-2b）雾化治疗儿童呼吸道病毒感染性疾病（RVI）的临床效果。方法 选取2019年3月-2020年12月我院儿科收治的80例RVI患儿为研究对象，采用随机数字表法分为对照组和观察组，各40例。对照组行常规治疗，观察组则在其基础上加用rhIFNα-2b雾化治疗。比较两组临床疗效、症状改善时间、炎性指标[嗜酸性粒细胞阳离子蛋白（ECP）及嗜酸性粒细胞（EOS）]、免疫球蛋白指标[免疫球蛋白G（IgG）、免疫球蛋白A（IgA）]、药物不良反应以及病毒感染复发率。结果 观察组治疗总有效率较对照组高（P＜0.05）；观察组的症状改善时间（退热时间、止咳时间、啰音消失时间）均短于对照组（P＜0.05）；治疗后，两组ECP、EOS指标低于治疗前，IgG、IgA指标高于治疗前，且观察组ECP、EOS指标低于对照组，IgG、IgA指标高于对照组，差异有统计学意义（P＜0.05）；两组药物不良反应发生率比较，差异无统计学意义（P＞0.05）；治疗后3个月观察组未发现感染复发病例，而对照组的感染复发率为10.00%，差异有统计学意义（P＜0.05）。结论 rhIFNα-2b雾化治疗儿童RVI疗效肯定，可缩短患儿的症状改善时间，控制其炎性表达，同时改善机体免疫应答，降低复发风险，安全可行。
Abstract:
Objective To explore the clinical effect of recombinant human interferon α-2b （rhIFNα-2b） atomization in the treatment of children with respiratory viral infectious (RVI).Methods A total of 80 children with RVI admitted to our hospital from March 2019 to December 2020 were selected as the research objects, and they were divided into control group and observation group by random number table method, with 40 cases in each group. The control group was treated with routine treatment, while the observation group was treated with rhIFNα-2b atomization on the basis of routine treatment. The clinical efficacy, symptom improvement time, inflammatory indexes [eosinophil cationic protein (ECP) and eosinophils (EOS)], immunoglobulin indexes [immunoglobulin G (IgG), immunoglobulin A (IgA) ], adverse drug reactions and viral infection recurrence rates were compared between the two groups.Results The total effective rate in the observation group was higher than that in the control group (P<0.05). The symptom improvement time (antipyretic time, cough relieving time and rale disappearance time) in the observation group was shorter than that in the control group (P<0.05). After treatment, the ECP and EOS of the two groups were lower than those before treatment, IgG and IgA were higher than those before treatment, ECP and EOS of the observation group were lower than those of the control group, IgG and IgA were higher than those of the control group, and the differences were statistically significant (P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups (P>0.05). Three months after treatment, no recurrence of infection was found in the observation group, while the recurrence rate of infection in the control group was 10.00%, and the difference was statistically significant (P<0.05).Conclusion The effect of rhIFNα-2b atomization in the treatment of children with RVI is definite， which can shorten the time of symptom improvement in children， control its inflammatory expression， improve the immune response of the body, and reduce the risk of recurrence. It is safe and feasible.

参考文献/References:

1]滑丽芳.重组人干扰素α-2b雾化吸入治疗小儿毛细支气管炎临床观察[J].河北北方学院学报(自然科学版),2021,37(4):34-36.[2]Cerdeira Barreiro N,Santiago-García B,Casas I,et al.Detection of Respiratory Viruses in the Clinical Outcome of Children With Fever and Neutropenia[J].Pediatr Infect Dis J,2020,39(6):533-538.[3]李聪.雾化吸入重组人干扰素α2b注射液治疗小儿呼吸道合胞病毒肺炎的疗效观察[J].临床研究,2021,29(1):61-62.[4]蓝伟,姚鲜红.重组人干扰素雾化吸入治疗上呼吸道病毒性感染患儿的临床效果[J].医疗装备,2020,33(22):86-87.[5]王敏捷.观察雾化吸入重组人干扰素α2b注射液治疗小儿呼吸道合胞病毒肺炎的价值[J].中国实用医药,2020,15(33):97-98.[6]任华,高永伟,高春燕,等.rh-INFα2b治疗儿童毛细支气管炎的疗效及对免疫功能的调节作用[J].现代生物医学进展,2020,20(21):4191-4195.[7]朱占魁,王奇伟,刘鼎立,等.布地奈德联合重组人干扰素α-2b雾化吸入治疗小儿毛细支气管炎临床疗效及安全性分析[J].中华全科医学,2020,18(8):1316-1319,1357.[8]吴春美,辛毅.重组干扰素α-2b联合孟鲁司特治疗小儿嗜酸性粒细胞性支气管炎患者疗效及对血清炎症因子的影响[J].贵州医药,2020,44(7):1062-1063,1093.[9]高凯华.重组人干扰素α-2b雾化治疗儿童呼吸道病毒感染性疾病的临床效果观察[J].当代医学,2020,26(21):54-56.[10]刁敏,张冲林,赵秀侠.重组人干扰素α-2b联合布地奈德、异丙托溴铵雾化对小儿毛细支气管炎疗效及IL-18、IL-33的影响[J].中国细胞生物学学报,2020,42(3):485-490.[11]陈青,钟斌,李研,等.重组人干扰素α-2b喷雾剂治疗儿童急性上呼吸道感染疗效分析[J].生物医学工程与临床,2019,23(4):462-466.[12]刘连凤,史军然,薛红霞,等.重组人干扰素α1b雾化吸入治疗儿童上呼吸道病毒感染及预防儿童上呼吸道病毒感染诱发毛细支气管炎效果研究[J].临床误诊误治,2019,32(5):24-29.[13]樊沙沙.重组人干扰素α-1b雾化治疗小儿呼吸道病毒感染性疾病的疗效观察[J].医学理论与实践,2018,31(9):1349-1350.[14]赵伟文,邱永静.不同剂量重组人干扰素α-2b治疗小儿病毒性肺炎临床疗效的比较研究[J].临床合理用药杂志,2021,14(6):68-70.[15]Hasegawa K,Goto T,Hirayama A,et al.Respiratory Virus Epidemiology Among US Infants With Severe Bronchiolitis: Analysis of 2 Multicenter, Multiyear Cohort Studies[J].Pediatr Infect Dis J,2019,38(8):e180-e183.

相似文献/References:

[1]刘 亮.PCT和CRP联合检测对儿童呼吸道感染的临床意义[J].医学信息,2018,31(02):154.[doi:10.3969/j.issn.1006-1959.2018.02.059]
　LIU Liang.Clinical Significance of Combined Detection of PCT and CRP in Children with Respiratory Tract Infection[J].Medical Information,2018,31(23):154.[doi:10.3969/j.issn.1006-1959.2018.02.059]
[2]王媛媛.乙型肝炎患者血清免疫球蛋白检测的意义[J].医学信息,2018,31(18):155.[doi:10.3969/j.issn.1006-1959.2018.18.050]
　WANG Yuan-yuan.Significance of Detection of Serum Immunoglobulin in Patients with Hepatitis B[J].Medical Information,2018,31(23):155.[doi:10.3969/j.issn.1006-1959.2018.18.050]
[3]叶向荣.恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价[J].医学信息,2018,31(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
　YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Medical Information,2018,31(23):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
[4]张 翠.小儿豉翘清热颗粒治疗小儿急性上呼吸道感染的疗效及安全性研究[J].医学信息,2022,35(18):74.[doi:10.3969/j.issn.1006-1959.2022.18.018]
　ZHANG Cui.Study on Efficacy and Safety of Xiaoer Chiqiao Qingre Granules in Treatment of Acute Upper Respiratory Tract Infection in Children[J].Medical Information,2022,35(23):74.[doi:10.3969/j.issn.1006-1959.2022.18.018]
[5]钟晓琛.血常规联合C反应蛋白检验在小儿感染类型鉴别诊断中的价值[J].医学信息,2022,35(17):64.[doi:10.3969/j.issn.1006-1959.2022.17.015]
　ZHONG Xiao-chen.Value of Blood Routine Combined with C-reactive Protein Test in Differential Diagnosis of Infection Types in Children[J].Medical Information,2022,35(23):64.[doi:10.3969/j.issn.1006-1959.2022.17.015]
[6]郑晓婷,张满英,许智华,等.螃蟹过敏致多形红斑误诊为手足口病1例报道[J].医学信息,2020,33(21):187.[doi:10.3969/j.issn.1006-1959.2020.21.060]
[7]闫红林,杨永勤,汪 雯,等.老年肝衰竭临床特点及预后转归[J].医学信息,2021,34(05):65.[doi:10.3969/j.issn.1006-1959.2021.05.019]
　YAN Hong-lin,YANG Yong-qin,WANG Wen,et al.Clinical Characteristics and Prognostic Outcome of Elderly Liver Failure[J].Medical Information,2021,34(23):65.[doi:10.3969/j.issn.1006-1959.2021.05.019]
[8]席 瑾,王 静,王瑗瑗.2012-2019年新乡市50岁及以上艾滋病病毒感染者流行病学特征[J].医学信息,2021,34(18):138.[doi:10.3969/j.issn.1006-1959.2021.18.037]
　XI Jin,WANG Jing,WANG Yuan-yuan.Epidemiological Characteristics of Acquired Immuno Deficiency Syndrome Patients Aged 50 andOver in Xinxiang City from 2012 to 2019[J].Medical Information,2021,34(23):138.[doi:10.3969/j.issn.1006-1959.2021.18.037]
[9]张东艳,张 森,刘 华.病毒感染相关慢性阻塞性肺病急性加重的免疫机制及潜在靶点研究进展[J].医学信息,2022,35(08):25.[doi:10.3969/j.issn.1006-1959.2022.08.007]
　ZHANG Dong-yan,ZHANG Sen,LIU Hua.Research Progress on Immune Mechanism and Potential Targets of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Associated with Virus Infection[J].Medical Information,2022,35(23):25.[doi:10.3969/j.issn.1006-1959.2022.08.007]
[10]杨海燕,陈新宽,王加平,等.mNAP在细菌感染鉴别诊断中应用价值[J].医学信息,2022,35(04):118.[doi:10.3969/j.issn.1006-1959.2022.04.029]
　YANG Hai-yan,CHEN Xin-kuan,WANG Jia-ping,et al.Application of mNAP in Differential Diagnosis of Bacterial Infection[J].Medical Information,2022,35(23):118.[doi:10.3969/j.issn.1006-1959.2022.04.029]

更新日期/Last Update: 1900-01-01